An experimental mRNA cancer vaccine from Moderna and Merck, given with Merck’s Keytruda after surgery, cut the risk of melanoma returning or death by 42% compared with Keytruda alone in a late-stage trial, Reuters reported. The vaccine, intismeran, also reduced the risk of distant metastasis or death by 38%.
After a median follow-up of 24.6 months, 82.2% of patients on the combination were alive without recurrence at two years, compared with 70.0% on Keytruda alone, CancerNetwork (opens in new tab) reported. The trial enrolled 1,137 patients with resected high-risk melanoma, according to Scientific American (opens in new tab). Overall survival data are not yet mature, CancerNetwork (opens in new tab) reported.
“This is highly statistically significant. It is not by chance,” trial investigator Dr. Hussein Tawbi of the University of Texas MD Anderson Cancer Center said, Reuters reported. The results are scheduled to be presented Saturday at the European Society for Medical Oncology congress, Reuters reported, and have been accepted for publication in the New England Journal of Medicine, according to CancerNetwork (opens in new tab).
“These results reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer,” Moderna CEO Stéphane Bancel said, Scientific American (opens in new tab) reported. Moderna shares fell more than 20% after the results leaked on an oncology website, while Merck shares slipped about 0.7%, Reuters reported.
Moderna’s stock closed down more than 17% on Thursday, its worst day since Aug. 20, Yahoo Finance (opens in new tab) reported. CNBC (opens in new tab) reported an intraday drop of as much as 25%. More than $17 billion in market value was erased Thursday, according to Yahoo Finance (opens in new tab). The shares closed down more than 1% on Friday, Yahoo Finance (opens in new tab) reported.
A separate analysis showed a 58% reduction in the risk of recurrence or death after the six-month vaccine regimen, CNBC (opens in new tab) reported. The companies say it is still too early to determine whether the treatment helps patients live longer overall. “Such a [stock] reaction likely reflects inflated expectations into the full data release, rather than a true indictment on the efficacy of the combo therapy,” BMO Capital Markets analyst Evan Seigerman said in a research note, according to CNBC (opens in new tab).